179 related articles for article (PubMed ID: 36552912)
1. New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications.
Mastromarino MG; Lenzini A; Aprile V; Alì G; Bacchin D; Korasidis S; Ambrogi MC; Lucchi M
Diagnostics (Basel); 2022 Nov; 12(12):. PubMed ID: 36552912
[TBL] [Abstract][Full Text] [Related]
2. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
[TBL] [Abstract][Full Text] [Related]
3. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
4. Pleural mesothelioma classification update.
Beasley MB; Galateau-Salle F; Dacic S
Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
[TBL] [Abstract][Full Text] [Related]
5. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
7. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Galateau-Salle F; Churg A; Roggli V; Travis WD;
J Thorac Oncol; 2016 Feb; 11(2):142-54. PubMed ID: 26811225
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of histologic subtyping of malignant pleural mesothelioma.
Brcic L; Kern I
Transl Lung Cancer Res; 2020 Jun; 9(3):924-933. PubMed ID: 32676358
[TBL] [Abstract][Full Text] [Related]
10. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
[TBL] [Abstract][Full Text] [Related]
11. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
Nicholson AG; Sauter JL; Nowak AK; Kindler HL; Gill RR; Remy-Jardin M; Armato SG; Fernandez-Cuesta L; Bueno R; Alcala N; Foll M; Pass H; Attanoos R; Baas P; Beasley MB; Brcic L; Butnor KJ; Chirieac LR; Churg A; Courtiol P; Dacic S; De Perrot M; Frauenfelder T; Gibbs A; Hirsch FR; Hiroshima K; Husain A; Klebe S; Lantuejoul S; Moreira A; Opitz I; Perol M; Roden A; Roggli V; Scherpereel A; Tirode F; Tazelaar H; Travis WD; Tsao MS; van Schil P; Vignaud JM; Weynand B; Lang-Lazdunski L; Cree I; Rusch VW; Girard N; Galateau-Salle F
J Thorac Oncol; 2020 Jan; 15(1):29-49. PubMed ID: 31546041
[TBL] [Abstract][Full Text] [Related]
12. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
13. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
14. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
15. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.
Rossi G; Righi L; Barbisan F; Tiseo M; Spagnolo P; Grosso F; Pisapia P; Malapelle U; Sculco M; Dianzani I; Abate-Daga L; Davolio MC; Ceresoli GL; Galetta D; Pasello G; Novello S; Bironzo P
J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673021
[TBL] [Abstract][Full Text] [Related]
16. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
17. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for Pathologic Diagnosis of Mesothelioma.
Husain AN; Chapel DB; Attanoos R; Beasley MB; Brcic L; Butnor K; Chirieac LR; Churg A; Dacic S; Galateau-Salle F; Hiroshima K; Hung YP; Klebe S; Krausz T; Khoor A; Litzky L; Marchevsky A; Nabeshima K; Nicholson AG; Pavlisko EN; Roden AC; Roggli V; Sauter JL; Schulte JJ; Sheaff M; Travis WD; Tsao MS; Walts AE; Colby TV
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38586983
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
[TBL] [Abstract][Full Text] [Related]
20. Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.
Savic I; Myers J
Acta Med Acad; 2021 Apr; 50(1):197-208. PubMed ID: 34075773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
